Cargando…

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma

Detalles Bibliográficos
Autores principales:	Shan, Huizhuang, Cao, Yang, Xiao, Xinhua, Liu, Meng, Wu, Yunzhao, Zhu, Qi, Xu, Hanzhang, Lei, Hu, Yao, Zhujun, Wu, Yingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338474/ https://www.ncbi.nlm.nih.gov/pubmed/32632092 http://dx.doi.org/10.1038/s41392-020-00236-1

Ejemplares similares

YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells
por: Wang, Yingying, et al.
Publicado: (2018)

Sinomenine derivative YL064: a novel STAT3 inhibitor with promising anti-myeloma activity
por: Wang, Yingying, et al.
Publicado: (2018)

Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
por: Mao, Shihui, et al.
Publicado: (2021)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1
por: Li, Lingxiao, et al.
Publicado: (2015)

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
por: Muenchow, Alina, et al.
Publicado: (2020)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
por: Shi, Yuanfei, et al.
Publicado: (2022)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells
por: Pandey, Manoj K., et al.
Publicado: (2013)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
por: Inoue, Chisato, et al.
Publicado: (2018)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells
por: Valdez, Benigno C., et al.
Publicado: (2022)

Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy
por: Sun, Xiao-Xin, et al.
Publicado: (2021)

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
por: Cao, Yang, et al.
Publicado: (2021)

ELL targets c-Myc for proteasomal degradation and suppresses tumour growth
por: Chen, Yu, et al.
Publicado: (2016)

Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins
por: Sasada, Manabu, et al.
Publicado: (2019)

Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines
por: Xiang, Benedict Lian Shi, et al.
Publicado: (2020)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

Synergistic cytotoxicity of perifosine and ABT‐737 to colon cancer cells
por: Adamová, Barbora, et al.
Publicado: (2022)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
por: Ko, Tun Kiat, et al.
Publicado: (2014)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1
por: Luedtke, Daniel A., et al.
Publicado: (2018)

Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
por: Shi, Yuan-Fei, et al.
Publicado: (2020)

Targeting deubiquitinating enzymes in cancer stem cells
por: Lei, Hu, et al.
Publicado: (2017)

Author Correction: ELL targets c-Myc for proteasomal degradation and suppresses tumour growth
por: Chen, Yu, et al.
Publicado: (2023)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
por: Benito, Juliana M., et al.
Publicado: (2015)

USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia
por: Shan, Huizhuang, et al.
Publicado: (2018)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8j3k9mokbrq8e3jb7ic8cfhp5v